87 completed, 11 terminated, 3 unknown, 3 withdrawn. 106 Phase 3, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 106 | Completed 87, Terminated 11, Unknown 3, Withdrawn 3, Recruiting 2 |
| Phase 2 | 8 | Completed 5, Terminated 2, Withdrawn 1 |
Follow Risperidone: new trials by email Literature Review of Risperidone trials Research Report on Risperidone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications Roluperidone, risperidone, aripiprazole - Negative Symptoms of Schizophrenia | Phase 3 | Recruiting | Minerva Neurosciences | 380 | 2026-04-23 | 2026-07-28 |
| A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder LYN-005 (risperidone), Placebo for LYN-005, IR Risperidone - Schizophrenia, Schizoaffective Disorder | Phase 3 | Withdrawn | Lyndra Inc. | 2025-04-18 | 2025-04-08 | |
| Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. Lumateperone 42 mg, Risperidone 2 mg - Apathy, Schizophrenia | Phase 3 | Recruiting | Louisiana State University Health Sciences Center Shreveport | 80 | 2024-06-01 | 2024-07-01 |
| Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005 LYN-005, Risperidone - Schizophrenia, Schizoaffective Disorder | Phase 3 | Completed | Lyndra Inc. | 83 | 2023-04-13 | 2024-10-24 |
| A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia TV-46000, Placebo - Schizophrenia | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 336 | 2019-04-17 | 2022-12-07 |
| Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia TV-46000, Placebo - Schizophrenia | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 544 | 2018-04-27 | 2023-03-10 |
| Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety? RisperiDONE 0.5 MG - Anxiety State | Phase 3 | Terminated | Marion Trousselard | 120 | 2017-09-01 | 2022-08-04 |
| Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia Lu AF35700, Risperidone, Olanzapine - Treatment-resistant Schizophrenia | Phase 3 | Terminated | H. Lundbeck A/S | 119 | 2017-07-20 | 2020-01-21 |
| Comparison of the Effectiveness of Brexpiprazole With That of Risperidone brexpiprazole, risperidone - Schizophrenia | Phase 3 | Withdrawn | H. Lundbeck A/S | 2016-06-01 | 2016-08-01 | |
| Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia Risperidone, Olanzapine, Lu AF35700 - Schizophrenia | Phase 3 | Completed | H. Lundbeck A/S | 1098 | 2016-04-01 | 2019-11-25 |
| Safety and Tolerability of Risperidone Implants Risperidone implant - Schizophrenia | Phase 3 | Completed | Braeburn Pharmaceuticals | 140 | 2016-04-01 | 2020-02-19 |
| A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform Aripiprazole, Haloperidol, Olanzapine - Schizophrenia, Psychotic Disorders | Phase 3 | Completed | Janssen Scientific Affairs, LLC | 337 | 2015-07-08 | 2025-04-29 |
| A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment ITI-007, Risperidone, Placebo - Schizophrenia | Phase 3 | Completed | Intra-Cellular Therapies, Inc. | 696 | 2015-06-01 | 2025-10-02 |
| Pharmacovigilance in Gerontopsychiatric Patients Phenobarbital, Phenytoin, Carbamazepine - Dementia, Depression | Phase 3 | Terminated | Hannover Medical School | 407 | 2015-01-01 | 2018-02-28 |
| Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia RBP-7000 - Schizophrenia | Phase 3 | Completed | Indivior Inc. | 500 | 2014-06-01 | 2018-09-28 |
| Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients RBP-7000, Placebo, Risperidone - Schizophrenia | Phase 3 | Completed | Indivior Inc. | 354 | 2014-04-01 | 2018-10-26 |
| A Clinical Trial of Lurasidone in Treatment of Schizophrenia Lurasidone tablets, Risperidone tablets - Schizophrenia | Phase 3 | Completed | Marubeni Pharmaceuticals (Suzhou) Co., Ltd. | 388 | 2013-12-01 | 2019-11-15 |
| Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia Iloperidone, Risperidone - Schizophrenia | Phase 3 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 288 | 2013-11-01 | 2015-05-27 |
| Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis Discontinuation antipsychotic treatment, Antipsychotic treatment - Psychosis Nos/Other | Phase 3 | Unknown | Fundación Pública Andaluza Progreso y Salud | 104 | 2012-11-01 | 2014-12-05 |
| A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder Risperidone, Placebo - Autistic Disorder in Children and Adolescents | Phase 3 | Completed | Janssen Pharmaceutical K.K. | 39 | 2012-09-01 | 2015-10-15 |
Showing 20 of 106. Sign in to see all of them.
Schizophrenia (61) · Psychotic Disorders (26) · Bipolar Disorder (16) · Mania (7) · Mental Disorders (7) · Dementia (6) · Alzheimer Disease (5) · Anxiety Disorders (5) · Depression (5) · Attention Deficit and Disruptive Behavior Disorders (4) · Autistic Disorder (4) · Attention Deficit Disorder with Hyperactivity (3) · Conduct Disorder (3) · Dementia, Vascular (3) · Depressive Disorder, Major (3)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (24) · Janssen, LP (7) · AstraZeneca (5) · H. Lundbeck A/S (5) · Janssen Pharmaceutica N.V., Belgium (5) · Janssen Pharmaceutical K.K. (3) · Janssen-Ortho Inc., Canada (3) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (3) · Tanabe Pharma Corporation (3) · Indivior Inc. (2) · Lyndra Inc. (2) · Marubeni Pharmaceuticals (Suzhou) Co., Ltd. (2) · Otsuka Pharmaceutical Development & Commercialization, Inc. (2) · Teva Branded Pharmaceutical Products R&D, Inc. (2) · University of Illinois at Chicago (2)
United States (36) · Japan (7) · Spain (7) · Bulgaria (6) · Canada (6) · China (6) · Finland (6) · France (6) · Russia (6) · Taiwan (6) · Czechia (5) · Germany (5) · Estonia (4) · Mexico (4) · Poland (4)
Andree Daigneault, Dr. (1) · Arnon Aharon, MD (1) · Ayal Schaffer, Dr. (1) · Barbara Geller, MD (1)
PMID 25978742, PMID 37811711, PMID 40730715, PMID 41272239, PMID 10084637, PMID 10496251, PMID 12091192, PMID 12153826, PMID 12218423, PMID 12562742, PMID 12633121, PMID 12777271, PMID 15169694, PMID 15323593, PMID 15492353, PMID 15572276, PMID 16086617, PMID 16135859, PMID 16505133, PMID 16965196, PMID 17284127, PMID 17335331, PMID 17606657, PMID 17606658, PMID 17854242, PMID 17975181, PMID 18007568, PMID 18312044, PMID 18384186, PMID 18642974, PMID 18681749, PMID 19042026, PMID 19102734, PMID 19182179, PMID 19922552, PMID 20035579, PMID 20227682, PMID 20384598, PMID 20732794, PMID 20820795, PMID 20926264, PMID 21092748, PMID 22213771, PMID 22265362, PMID 22395527, PMID 22676070, PMID 22917200, PMID 22952075, PMID 23446197, PMID 23849714
2004 (1), 2005 (1), 2014 (1), 2015 (1), 2016 (1), 2018 (1), 2019 (1), P01HD026927 (1), R21MH080026 (1), U01MH064846 (1), U01MH064850 (1), U01MH064868 (1), U01MH064869 (1), U01MH064887 (1), U01MH064911 (1)